Teclistamab Shows Promise in Refractory Autoantibody-Mediated Coagulation Disorders – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Johannes Thaler et al, adding:
“Teclistamab for the treatment of autoantibody-mediated coagulation disorders.
In a retrospective series, seven patients with refractory or rapidly progressive autoantibody-mediated coagulation disorders received teclistamab: two had acquired von Willebrand disease, two acquired factor XI deficiency, and three catastrophic antiphospholipid syndrome.
All achieved reported complete remission, at a median of 24 weeks.
Three patients developed grade 1 cytokine release syndrome, and all received immunoglobulin replacement.
These uncontrolled observations support further investigation of plasma cell-directed treatment; they cannot establish comparative efficacy or safety.”
Title: Teclistamab for the treatment of autoantibody-mediated coagulation disorders
Authors: Johannes Thaler, Karoline Gleixner, Lisbeth Eischer, Gabriel Kammerer, Joachim Rettl, Lisa Sailer, Christian Sillaber, Peter Quehenberger, Maria Theresa Krauth, Paul Knöbl, Cihan Ay, Hermine Agis
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 4, 2026, 12:53Douglas Tavares: Why Patient Blood Management Remains Underused Despite Decades of Evidence
-
Nov 4, 2026, 12:40Jasem Albasri: Innovation and Progress in Laboratory Medicine
-
Nov 4, 2026, 12:34Giovanna Gao: Exploring Prothrombotic Mechanisms in ITP
-
Nov 4, 2026, 12:29Gopal Patidar: ISBT Addresses Common Misconceptions About Transfusion Reactions
-
Nov 4, 2026, 10:39Majed Tolah: 31 Years After Heart Transplant – A Rare Thrombotic Complication
-
Nov 4, 2026, 10:24Abhishek Jain: Vessel-on-a-Chip – Exploring Viral-Induced Endothelial Dysfunction
-
Nov 4, 2026, 10:11Balancing Thrombosis and Bleeding in Acute Leukemia – Seminars in Thrombosis and Hemostasis
-
Nov 4, 2026, 10:00Harmonizing Bleeding Outcomes in Hemophilia – JTH
-
Nov 4, 2026, 07:38Augustina Isioma Ikusemoro: Advancing Transfusion Medicine Through Innovation and Collaboration